Organigram Agrees to Buy Aurora Cannabis for $561M
Organigram Global will acquire Aurora Cannabis after Curaleaf's earlier hostile bid was rebuffed.
Updated on Nov. 3, 2026 in Business Strategy
Organigram Global Inc. signed a deal to buy Aurora Cannabis Inc. in a transaction valuing Aurora at $561 million. Aurora shareholders can take $7.80 per share in cash, 5.8626 Organigram shares per share, or a combination, subject to caps.
Why it matters
The agreement follows a strategic review at Aurora and a rejected hostile offer from Curaleaf Holdings earlier in 2026. Organigram's CEO described the transaction as a defining step in building a disciplined, global cannabis leader.
The deal values Aurora at $561 million, with cash consideration capped at $253.6 million and share issuance limited to 205.8 million shares. That compares with Curaleaf's earlier hostile proposal, valued at US$5 per Aurora share based on its Oct. 2 closing price, which combined 0.4013 Curaleaf shares with US$1 cash.
The players
Organigram Global Inc.
Organigram is a Canadian licensed cannabis producer that is acquiring Aurora under the signed agreement.
Aurora Cannabis Inc.
Aurora is a major Canadian cannabis company whose board pursued a strategic review before agreeing to the sale.
Curaleaf Holdings Inc.
Curaleaf is a U.S.-based cannabis operator headquartered in Stamford, Connecticut, whose hostile bid for Aurora was rebuffed.
The details
Under the terms, Aurora shareholders may elect $7.80 in cash or 5.8626 Organigram shares for each Aurora share, or a mix of both. The offer follows Curaleaf's unsolicited proposal, which Aurora rejected earlier in the year.
Timeline
Earlier in 2026: Curaleaf made a hostile offer for Aurora Cannabis, which was rebuffed.
Oct. 2, 2026: Curaleaf's closing share price used to value its proposal.
Nov. 3, 2026: Organigram signed the deal to buy Aurora Cannabis.
Market Landscape
The transaction extends a wave of consolidation among licensed cannabis producers seeking scale in a crowded North American market. Curaleaf's rejected hostile bid shows that contested takeovers have become a recurring tactic in the sector's ongoing restructuring.
For shareholders of Aurora, the choice between $7.80 in cash and 5.8626 Organigram shares per share determines the form of their return. Investors should weigh the cash cap and share cap, since elections beyond those limits may not be fully honored.
The takeaway
Shareholders in a takeover should compare cash and stock consideration against the caps that govern each election. Reviewing the allocation terms before choosing can help avoid an unexpected mix of consideration.
Further reading
Explore more coverage in our Business Strategy section.
